Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial

J. Taieb 1 K. Le Malicot 2 R. Balogoum 3, 4, 5 J. Tabernero 6 E. Mini 7 G. Folprecht 8 L. Van Laethem 9 J-F. Emile 10 C. Mulot 5 S. Fratté 11 C-B. Levaché 12 L. Saban-Roche 13 J. Thaler 14 L. Nørgård Petersen 15 E. Sanchez 16 J. Bridgewater G. Perkins 3, 4, 5 Come Lepage 17, 18 A. Zaanan 1 P. Laurent-Puig 3, 4, 5
1 Service de gastroenterologie [CHU Georges Pompidou]
2 Service de Biostatistique
3 CRESS (U1153 / UMR_A 1125) - Centre de Recherche Épidémiologie et Statistique Sorbonne Paris Cité
4 HEGP - Hôpital Européen Georges Pompidou [APHP]
5 MEPPOT - U1147 - Médecine Personnalisée, Pharmacogénomique, Optimisation Thérapeutique
6 Vall d'Hebron University Hospital [Barcelona]
7 Dpt of Internal Medicine, Section of Immunoallergology and Respiratory [Florence] Diseases
8 Carl Gustav Carus University Hospital
9 Département de médecine interne [hôpital Erasme]
10 Service de pathologie [CHU Ambroise Paré]
11 CH Belfort-Montbéliard
12 Polyclinique Francheville
13 Institut de Cancérologie de la Loire Lucien Neuwirth
14 Klinikum Wels Grieskirchen
15 Rigshospitalet [Copenhagen]
16 Instituto Português de Oncologia de Francisco Gentil
17 Service d'hépato-gastroentérologie et cancérologie digestive (CHU de Dijon)
18 LNC - Lipides - Nutrition - Cancer (U866)
Abstract : Background: RAS mutations have been shown to confer resistance to anti-EGFR treatment. We assessed here the results of the PETACC8 trial (Cetuximab + FOLFOX vs FOLFOX) in full wild type (WT) patients (pts) (RAS & BRAF). The prognostic impact of individual rare RAS and BRAF mutations has been tested. Methods: Exons 2, 3 and 4 of KRAS and NRAS as well as BRAF exon 11 and 15 have been sequenced, using the ampliseq colon lung cancer panel V2, among the pts who have signed informed consent for translational research. The impact of cetuximab on Time To Recurrence (TTR), Disease Free Survival (DFS) and Overall Survival (OS), has been investigated in pts RAS WT, RAS & BRAF double WT tumors and in pts with rare...
Keywords : RAS mutations FOLFOX
Type de document :
Communication dans un congrès
41st ESMO Congress (ESMO 2016), Oct 2016, Copenhague, Denmark. Annals of oncology, 27 (suppl_6), pp.4610, 2016, Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark. 〈https://academic.oup.com/annonc/article-abstract/27/suppl_6/461O/2799200/Adjuvant-FOLFOX-cetuximab-vs-FOLFOX-in-full-RAS?redirectedFrom=fulltext〉. 〈10.1093/annonc/mdw370.10〉
Liste complète des métadonnées
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01494512
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : jeudi 23 mars 2017 - 15:48:48
Dernière modification le : mardi 27 mars 2018 - 16:19:37

Identifiants

Collections

UNIV-PARIS5 | LNC-UMR866 | USPC | INRA | ENSBANA

Citation

J. Taieb, K. Le Malicot, R. Balogoum, J. Tabernero, E. Mini, et al.. Adjuvant FOLFOX+ cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial. 41st ESMO Congress (ESMO 2016), Oct 2016, Copenhague, Denmark. Annals of oncology, 27 (suppl_6), pp.4610, 2016, Abstract Book of the 41st ESMO Congress (ESMO 2016), 7-11 October 2016, Copenhagen, Denmark. 〈https://academic.oup.com/annonc/article-abstract/27/suppl_6/461O/2799200/Adjuvant-FOLFOX-cetuximab-vs-FOLFOX-in-full-RAS?redirectedFrom=fulltext〉. 〈10.1093/annonc/mdw370.10〉. 〈hal-01494512〉

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

142

Contact

support.ccsd.cnrs.fr
hal.support@ccsd.cnrs.fr
Logo CCSD